studies

es-BC - TNBC - NA - PDL1 positive, anti-PD-(L)1 vs. all, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias pCR detailed resultsIMpassion-031 (PDL1>1%), 2020 2.23 [1.16; 4.30] 2.23[1.16; 4.30]IMpassion-031 (PDL1>1%), 202010%154NAnot evaluable0.55.01.0relative treatment effectwww.metaEvidence.org2024-11-01 00:15 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 306 - treatments: 367,851,361,602,1070,671,865,744,696,1083,1281,1282,1283,1082,866,852,417,603,1051,876,853,1018,661,673,1049,1440,1561,854,374,953,672,1080,1560,1073,862,1562,1565,855,360,719,721,720,842,642,674,1085,863,503,847,982,359,575,577,576,869,1081,981,875,505,952,1021,1079,767,1071,1074,873,561,644,1251,1044,724,874,1043,1041,1042,940,1258,1563